Compare GD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GD | VRTX |
|---|---|---|
| Founded | 2019 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.9B | 96.6B |
| IPO Year | N/A | 1991 |
| Metric | GD | VRTX |
|---|---|---|
| Price | $341.60 | $431.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 26 |
| Target Price | $342.41 | ★ $489.17 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 10-24-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 17.69 | N/A |
| EPS | ★ 15.44 | 14.22 |
| Revenue | ★ $51,509,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $12.01 | $10.95 |
| Revenue Next Year | $4.48 | $9.55 |
| P/E Ratio | ★ $22.13 | $30.49 |
| Revenue Growth | ★ 11.86 | 10.33 |
| 52 Week Low | $239.20 | $362.50 |
| 52 Week High | $360.50 | $519.68 |
| Indicator | GD | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 55.18 |
| Support Level | $334.35 | $418.53 |
| Resistance Level | $343.06 | $435.85 |
| Average True Range (ATR) | 5.66 | 9.82 |
| MACD | -0.87 | -0.47 |
| Stochastic Oscillator | 37.39 | 65.37 |
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.